| Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition (NCT03275597) | University of Wisconsin, Madison | 2018-02-20 |
| A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT03296163) | mAbxience Research S.L. | 2018-02-06 |
| A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients (NCT03486119) | Yonsei University | 2018-02-05 |
| Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer (NCT03377023) | H. Lee Moffitt Cancer Center and Research Institute | 2018-02-02 |
| Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC (NCT03525782) | The First Affiliated Hospital of Guangdong Pharmaceutical University | 2018-02-01 |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors (NCT03169738) | ImmunityBio, Inc. | 2018-02-01 |
| First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) (NCT03401385) | Daiichi Sankyo Co., Ltd. | 2018-01-31 |
| A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer (NCT03392246) | Dana-Farber Cancer Institute | 2018-01-31 |
| Dabrafenib and/or Trametinib Rollover Study (NCT03340506) | Novartis Pharmaceuticals | 2018-01-26 |
| BT1718 in Patients with Advanced Solid Tumours. (NCT03486730) | Cancer Research UK | 2018-01-24 |
| Exhaled Breath Particles in Lung Cancer (NCT05395611) | Lund University Hospital | 2018-01-23 |
| SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial (NCT03306680) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2018-01-19 |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (NCT03319459) | Fate Therapeutics | 2018-01-18 |
| Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid (NCT03413358) | BeiJing Yijiayi Medicine Techonoloy Co., Ltd. | 2018-01-15 |
| Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy (NCT03416972) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2018-01-11 |
| NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy" (NCT03771404) | Hellenic Oncology Research Group | 2018-01-05 |
| Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies (NCT03367819) | Sanofi | 2018-01-04 |
| Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer (NCT03679936) | Fifth Affiliated Hospital, Sun Yat-Sen University | 2018-01-03 |
| Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment (NCT05205226) | Hunan Province Tumor Hospital | 2018-01-02 |
| Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer (NCT03647111) | Hunan Province Tumor Hospital | 2018-01-01 |
| Understanding Evidence-Based Practice Patterns in Advanced NSCLC (NCT03107156) | Carevive Systems, Inc. | 2018-01-01 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer (NCT04835025) | Tongji Hospital | 2018-01-01 |
| Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody (NCT03282435) | Dalian University | 2018-01-01 |
| A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases (NCT03427541) | Tang-Du Hospital | 2017-12-31 |
| A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (NCT03195491) | Bristol-Myers Squibb | 2017-12-25 |
| Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies (NCT03317496) | Pfizer | 2017-12-21 |
| A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors (NCT03289962) | Genentech, Inc. | 2017-12-21 |
| Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (NCT03334617) | AstraZeneca | 2017-12-18 |
| Biomarkers for Risk Stratification in Lung Cancer (NCT03774758) | University of California, San Francisco | 2017-12-17 |
| Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (NCT03345810) | AIO-Studien-gGmbH | 2017-12-14 |
| Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer (NCT03237377) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-12-12 |
| Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (NCT03307759) | Peter MacCallum Cancer Centre, Australia | 2017-12-07 |
| Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer (NCT03262948) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2017-12-01 |
| A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer (NCT03429192) | Tianjin Chest Hospital | 2017-12-01 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer (NCT03413956) | Jiangsu Cancer Institute & Hospital | 2017-12-01 |
| A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer (NCT03427567) | Tongji Hospital | 2017-12-01 |
| A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients (NCT03429673) | China-Japan Friendship Hospital | 2017-12-01 |
| A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer (NCT03451526) | Tang-Du Hospital | 2017-12-01 |
| Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT03358875) | BeiGene | 2017-11-30 |
| Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer (NCT03087760) | Abramson Cancer Center at Penn Medicine | 2017-11-29 |
| T-Cell PET Imaging With [18F]F-AraG in Lung Cancer (NCT03311672) | University of California, San Francisco | 2017-11-26 |
| A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients (NCT03373955) | Sichuan University | 2017-11-23 |
| A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (NCT03343613) | Eli Lilly and Company | 2017-11-17 |
| Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers (NCT03195699) | Tvardi Therapeutics, Incorporated | 2017-11-15 |
| Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (NCT03366064) | Asan Medical Center | 2017-11-09 |
| Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea (NCT03271554) | Hoffmann-La Roche | 2017-11-09 |
| Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study (NCT03306992) | University of Utah | 2017-11-07 |
| Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC (NCT02947113) | The Netherlands Cancer Institute | 2017-11-01 |
| Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 (NCT03360929) | LYZZ Alpha Holding Ltd | 2017-10-30 |
| Safety and Efficacy of Xalkori ROS1 (NCT03375242) | Pfizer | 2017-10-25 |
| Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients (NCT03137264) | AstraZeneca | 2017-10-24 |
| Adjuvant CCRT vs CT in Minimal N2 NSCLC (NCT01066234) | Samsung Medical Center | 2017-10-23 |
| Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing (NCT03320044) | Peking University People's Hospital | 2017-10-18 |
| Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance (NCT03267654) | Qilu Pharmaceutical Co., Ltd. | 2017-10-12 |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (NCT03307785) | Tesaro, Inc. | 2017-10-12 |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer (NCT03215810) | H. Lee Moffitt Cancer Center and Research Institute | 2017-10-11 |
| Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer (NCT03217071) | Sue Yom | 2017-10-04 |
| Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents (NCT03242915) | University of Michigan Rogel Cancer Center | 2017-10-03 |
| IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer (NCT03258671) | LuBing | 2017-10-01 |
| Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer (NCT04425681) | Second Affiliated Hospital of Nanchang University | 2017-10-01 |
| ENB Robotic ICG Guided Surgery: A Novel Technique for Targeting Small Lung Tumors (NCT02570958) | St. Joseph's Healthcare Hamilton | 2017-10-01 |
| X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib (NCT03215693) | Betta Pharmaceuticals Co., Ltd. | 2017-09-28 |
| Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC (NCT03177291) | H. Lee Moffitt Cancer Center and Research Institute | 2017-09-26 |
| Pembrolizumab + Idelalisib for Lung Cancer Study (NCT03257722) | Asha Nayak | 2017-09-26 |
| Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) (NCT02920450) | University of Florida | 2017-09-25 |
| A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT03178552) | Hoffmann-La Roche | 2017-09-22 |
| A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (NCT03267316) | Cantargia AB | 2017-09-19 |
| Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) (NCT03285321) | Greg Durm, MD | 2017-09-15 |
| Study of High Efficient Killing Cell Therapy for Advanced NSCLC (NCT03193567) | Ruijin Hospital | 2017-09-14 |
| A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC (NCT03202940) | Massachusetts General Hospital | 2017-09-14 |
| Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer (NCT03198923) | Wenxiang Wang | 2017-09-13 |
| Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (NCT03087448) | University of California, San Francisco | 2017-09-09 |
| A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC (NCT03150875) | Innovent Biologics (Suzhou) Co. Ltd. | 2017-09-01 |
| Cell Free DNA for the Diagnosis and Treatment in Early NSCLC (NCT03791034) | Samsung Medical Center | 2017-08-28 |
| Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer (NCT03481114) | Albert Einstein College of Medicine | 2017-08-28 |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers (NCT03190174) | Sarcoma Oncology Research Center, LLC | 2017-08-24 |
| A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (NCT03215706) | Bristol-Myers Squibb | 2017-08-24 |
| Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors (NCT03392233) | RenJi Hospital | 2017-08-18 |
| A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms (NCT03219268) | MacroGenics | 2017-08-18 |
| mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer (NCT03196986) | Beijing Mabworks Biotech Co., Ltd. | 2017-08-15 |
| Pembrolizumab + CVA21 in Advanced NSCLC (NCT02824965) | Olivia Newton-John Cancer Research Institute | 2017-08-09 |
| the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) (NCT03264794) | Jiangsu Famous Medical Technology Co., Ltd. | 2017-08-01 |
| MRI Adaptive Replanning Using ViewRay (NCT02950792) | University of Miami | 2017-08-01 |
| Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT03245177) | Prof Corinne Faivre-Finn | 2017-08-01 |
| Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA (NCT03228277) | Konkuk University Medical Center | 2017-07-17 |
| Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 (NCT03003468) | Lawrence Feldman, MD | 2017-07-11 |
| Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT02730247) | Liza Villaruz, MD | 2017-07-05 |
| Resistance to Oral Therapy in Lung Cancer (NCT04546282) | University Hospital, Montpellier | 2017-07-01 |
| Concordance of Inivata Liquid Biopsy With Standard Tissue Biopsy (NCT03116633) | Inivata | 2017-06-30 |
| Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC (NCT03201146) | West China Hospital | 2017-06-27 |
| Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) (NCT03117049) | Ono Pharmaceutical Co., Ltd. | 2017-06-13 |
| Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors (NCT03138889) | Nektar Therapeutics | 2017-06-09 |
| Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (NCT03090737) | Bristol-Myers Squibb | 2017-06-02 |
| Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient (NCT03132493) | Spanish Lung Cancer Group | 2017-06-01 |
| Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors (NCT02538432) | University of Maryland, Baltimore | 2017-06-01 |
| PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors (NCT03149549) | CytomX Therapeutics | 2017-06-01 |
| Modifying Your Diet to Support Muscle During Cancer Treatment. (NCT03010657) | University of Alberta | 2017-06-01 |
| Explore Intra-tumor Heterogeneity and Prognostic Value of Postoperative Blood ctDNA of ⅡA - ⅢA Stage Non-squamous NSCLC Based on the Capture-based Sequencing and UMI Technology of Burning Rock (NCT03337711) | Sun Yat-sen University | 2017-05-24 |